Stock Events

Stock Events

Galectin Therapeutics 

€3.92
28
+€0.24+6.52% Friday 19:56

Statistics

Day High
3.96
Day Low
3.68
52W High
5.85
52W Low
1.73
Volume
-
Avg. Volume
-
Mkt Cap
395.33M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q1 2026
Q2 2026
Next
-0.12
-0.1
-0.07
-0.04
Expected EPS
-0.04304
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-27.06MNet Income

Analyst Ratings

8.35Average Price Target
The highest estimate is 8.35.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHPN.STU. It's not an investment recommendation.
Ethereum
7
ETH.CRYPTO
Pfizer
7
PFE
Amazon
6
AMZN
Coca-Cola
6
KO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.33B
Madrigal Pharmaceuticals is involved in developing therapies for nonalcoholic steatohepatitis (NASH), directly competing with Galectin's NASH treatment research.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.34M
Galmed Pharmaceuticals works on treatments for liver diseases like NASH, positioning it as a competitor in the same therapeutic area as Galectin.
Viking Therapeutics
VKTX
Mkt Cap3.75B
Viking Therapeutics is also focused on developing treatments for metabolic and endocrine disorders, including NASH, making them a competitor in the NASH treatment space.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a broad portfolio including liver disease treatments, competing with Galectin in the liver disease therapeutic area, especially in NASH.
Agios Pharmaceuticals
AGIO
Mkt Cap1.99B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, competing with Galectin in the metabolic disease space.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has a diverse biopharmaceutical portfolio that includes treatments for chronic diseases, indirectly competing with Galectin in the broader pharmaceutical market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's broad focus on innovative therapeutics for serious illnesses puts it in competition with Galectin, especially in areas like cancer and inflammatory diseases.

About

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Show more...
CEO
Joel Lewis
Employees
9
Country
United States
ISIN
US3632252025
WKN
000A1JV3R

Listings

STU
DE
PHPN.STU
F
DE
PHPN.F
MU
DE
PHPN.MU
XNAS
US
GALT

0 Comments

Share your thoughts

FAQ

What is Galectin Therapeutics stock price today?▼
The current price of PHPN.STU is €3.92 EUR — it has increased by +6.52% in the past 24 hours. Watch Galectin Therapeutics stock price performance more closely on the chart.
What is Galectin Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Galectin Therapeutics stocks are traded under the ticker PHPN.STU.
Is Galectin Therapeutics stock price growing?▼
PHPN.STU stock has risen by +15.98% compared to the previous week, the month change is a +49.62% rise, over the last year Galectin Therapeutics has showed a +3.7% increase.
What is Galectin Therapeutics market cap?▼
Today Galectin Therapeutics has the market capitalization of 395.33M
When is the next Galectin Therapeutics earnings date?▼
Galectin Therapeutics is going to release the next earnings report on November 16, 2026.
What were Galectin Therapeutics earnings last quarter?▼
PHPN.STU earnings for the last quarter are -0.12 EUR per share, whereas the estimation was -0.08 EUR resulting in a -55.56% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Galectin Therapeutics revenue for the last year?▼
Galectin Therapeutics revenue for the last year amounts to 0 EUR.
What is Galectin Therapeutics net income for the last year?▼
PHPN.STU net income for the last year is -27.06M EUR.
How many employees does Galectin Therapeutics have?▼
As of September 05, 2026, the company has 9 employees.
In which sector is Galectin Therapeutics located?▼
Galectin Therapeutics operates in the Health & Wellness sector.
When did Galectin Therapeutics complete a stock split?▼
The last stock split for Galectin Therapeutics was on March 23, 2012 with a ratio of 1:6.
Where is Galectin Therapeutics headquartered?▼
Galectin Therapeutics is headquartered in NORCROSS, United States.